#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Basal cell naevus syndrome Vulval cancer recurrent Pancreatic neuroendocrine tumour Liposarcoma metastatic Primary immunodeficiency syndrome B-cell lymphoma recurrent Li-Fraumeni syndrome Bulbospinal muscular atrophy congenital ABO haemolytic disease of newborn Malignant melanoma Postprandial hypoglycaemia Immune-mediated enterocolitis Biotinidase deficiency Exudative retinopathy Fms-like tyrosine kinase 3 positive More trials…

    Learn about Rare Diseases

    Marginal zone lymphoma refractory – Trials in Disease Cerebral arteriovenous malformation haemorrhagic Krabbe’s disease – Diagnostics Glomerulonephritis membranoproliferative – Basic Information Myxofibrosarcoma – Life with Disease Toxic epidermal necrolysis – Diagnostics Gaucher’s disease type III – Life with Disease Gaucher’s disease type I – Diagnostics Ewing’s sarcoma Hairy cell leukaemia recurrent – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ipratropium Bromide Bempedoic Acid Enasidenib Mesilate Finerenone Bemcentinib Raltegravir Alpha-Tocopherol Lbl-007 Ly3819469 Sodium Eribulin Mesylate Darolutamide Nelivaptan Highly Refined Fish Oil Ibrutinib [11C]Az14193391 Obexelimab Dinoprostone Pevonedistat Diazepam Vincristine Sulfate More therapies…

    Learn about Your Condition

    Rhabdomyosarcoma Gouty arthritis Pancreatitis chronic Alexander disease Substance use disorder Premature rupture of membranes Stargardt's disease Solitary fibrous tumour Atrial fibrillation Drug use disorder Periodontitis Noninfective chorioretinitis Apheresis Hereditary ataxia Biliary cancer metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Multiple sclerosis

  • Study on Stopping Dimethyl Fumarate and Drug Combination in Patients Aged 55+ with Inactive Relapsing-Remitting Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Diroximel Fumarate
    • Interferon Beta-1A
    • Peginterferon Beta-1A
    France

  • Study on Monitoring Ocrelizumab Levels for Personalized Treatment in Patients with Relapsing-Remitting and Primary Progressive Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    Czechia

  • Study on the Effects of Ozanimod on Inflammation in Patients with Relapsing Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Progressive relapsing multiple sclerosis
    • Multiple sclerosis
    • Relapsing-remitting multiple sclerosis
    Investigated Drugs:
    • Ozanimod
    Italy

  • Study on the Use of Mesenchymal Stem Cells and Sodium Chloride for Patients with Progressive Multiple Sclerosis

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Mesenchymal Stromal Cells, Ex Vivo Cultured
    • Sodium Chloride
    Norway

  • Study on Modafinil for Improving Cognitive Deficits in Multiple Sclerosis Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Modafinil
    Portugal

  • Study on the Effects of Ozanimod in Patients with Relapsing-Remitting Multiple Sclerosis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Multiple sclerosis relapse
    • Multiple sclerosis
    Investigated Drugs:
    • Ozanimod Hydrochloride
    Italy
Previous Page
1 2 3 4 … 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!